Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Gold Prices Climb as Middle East Ceasefire Talks Stir Market Optimism 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Gold Prices Drop Amid Iran Peace Talk Uncertainty and Stronger Dollar 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
